Artivion (AORT) Projected to Release Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Artivion to announce earnings of $0.0088 per share and revenue of $120.0170 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Artivion Trading Up 1.9%

NYSE:AORT opened at $27.52 on Thursday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25. The company has a market cap of $1.34 billion, a PE ratio of 114.67 and a beta of 1.26. The company has a 50 day simple moving average of $22.91 and a two-hundred day simple moving average of $31.85.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Weiss Ratings downgraded Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. Citizens Jmp lowered their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Friday, April 10th. Finally, Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Insider Transactions at Artivion

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AORT. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion during the 3rd quarter valued at approximately $27,000. Smartleaf Asset Management LLC raised its stake in Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after acquiring an additional 538 shares during the period. Kemnay Advisory Services Inc. bought a new stake in Artivion during the 4th quarter worth approximately $79,000. Quadrant Capital Group LLC purchased a new position in Artivion during the third quarter valued at approximately $92,000. Finally, iSAM Funds UK Ltd purchased a new position in Artivion during the third quarter valued at approximately $131,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.